Long-term safety and tolerability of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: Results from a phase III, randomized, controlled trial (ESTEEM 1)

Keyword(s):

Controlled Trial ◽

Severe Psoriasis ◽

Phase Iii ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

FRI0447 Long-Term (156-Week) Efficacy and Safety Profile of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from A Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 1)

10.1136/annrheumdis-2016-eular.3256 ◽

2016 ◽

Vol 75 (Suppl 2) ◽

pp. 597.2-598

Author(s):

A. Kavanaugh ◽

D.D. Gladman ◽

J.J. Gomez-Reino ◽

S. Hall ◽

E. Lespessailles ◽

...

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

THU0416 Disease Activity and Safety During Long-Term (104-Week) Treatment with Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (Palace 3)

10.1136/annrheumdis-2015-eular.2889 ◽

2015 ◽

Vol 74 (Suppl 2) ◽

pp. 348.2-349 ◽

Cited By ~ 3

Author(s):

C. Edwards ◽

F. Blanco ◽

J. Crowley ◽

C. Hu ◽

K. Shah ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase Iii ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

217. Long-Term (104-Week) Efficacy and Safety Profile of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Results from a Phase III, Randomized, Controlled Trial and Open-Label Extension (PALACE 1)

Rheumatology ◽

10.1093/rheumatology/kev089.104 ◽

2015 ◽

Keyword(s):

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Open Label ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Open Label Extension ◽

LB0001 Long-Term (52-Week) Results of a Phase 3, Randomized, Controlled Trial of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis

10.1136/annrheumdis-2013-eular.526 ◽

2013 ◽

Vol 72 (Suppl 3) ◽

pp. A163-A163 ◽

Cited By ~ 5

Author(s):

A. Kavanaugh ◽

P. J. Mease ◽

A. O. Adebajo ◽

J. Wollenhaupt ◽

C. Hu ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0377 Long-Term Safety and Tolerability of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: A Phase 3, Randomized, Controlled Trial

10.1136/annrheumdis-2014-eular.1575 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 730.2-730 ◽

Author(s):

A. Adebajo ◽

A. Wells ◽

C. Edwards ◽

A. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate‐to‐severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2)

British Journal of Dermatology ◽

10.1111/bjd.14164 ◽

2015 ◽

Vol 173 (6) ◽

pp. 1387-1399 ◽

Cited By ~ 201

Author(s):

C. Paul ◽

J. Cather ◽

M. Gooderham ◽

Y. Poulin ◽

U. Mrowietz ◽

...

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)

Journal of the American Academy of Dermatology ◽

10.1016/j.jaad.2014.01.682 ◽

2014 ◽

Vol 70 (5) ◽

pp. AB164 ◽

Keyword(s):

Controlled Trial ◽

Severe Psoriasis ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

Faculty Opinions recommendation of Efficacy and safety of apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate-to-severe plaque psoriasis over 52 weeks: a phase III, randomized controlled trial (ESTEEM 2).

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature ◽

10.3410/f.725781037.793521633 ◽

2016 ◽

Author(s):

Gil Yosipovitch ◽

Leigh Nattkemper

Keyword(s):

Plaque Psoriasis ◽

Controlled Trial ◽

Phase Iii ◽

Efficacy And Safety ◽

Severe Plaque Psoriasis ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

SAT0382 Palace 4, A Phase 3, Randomized, Controlled TRIAL of Apremilast, an Oral Phosphodiesterase 4 Inhibitor, for Treatment of Psoriatic Arthritis: Long-Term (52-WEEK) Improvements in Physical Function

10.1136/annrheumdis-2014-eular.1096 ◽

2014 ◽

Vol 73 (Suppl 2) ◽

pp. 732.1-732 ◽

Author(s):

A. Wells ◽

C. Edwards ◽

A.O. Adebajo ◽

A.J. Kivitz ◽

P. Bird ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Physical Function ◽

Controlled Trial ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽

212. Long-Term 52-Week Results of Palace 3, A Phase 3, Randomized, Controlled Trial of Apremilast, An Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis and Current Skin Involvement

Rheumatology ◽

10.1093/rheumatology/keu115.006 ◽

2014 ◽

Vol 53 (suppl_1) ◽

pp. i138-i139 ◽

Cited By ~ 8

Author(s):

Christopher J. Edwards ◽

Francisco J. Blanco ◽

Jeffrey Crowley ◽

ChiaChi Hu ◽

Randall M. Stevens ◽

...

Keyword(s):

Psoriatic Arthritis ◽

Controlled Trial ◽

Skin Involvement ◽

Phase 3 ◽

Phosphodiesterase 4 ◽

Randomized Controlled ◽